Skye Bioscience Investors Face Jan. 16 Deadline in Securities Class Action Over Nimacimab Disclosures

Overview

• A federal securities class action has been filed on behalf of Skye Bioscience shareholders covering November 4, 2024 through October 3, 2025.
• The complaint alleges Skye misrepresented the effectiveness and the clinical, regulatory, and commercial prospects of its lead drug candidate, nimacimab.
• On October 6, 2025, Skye reported Phase 2a topline data showing the nimacimab monotherapy arm failed the primary endpoint and exhibited lower-than-expected drug exposure.
• Following that disclosure, Skye’s shares fell about 60% to close at $1.90 on October 6, 2025.
• Investors have until January 16, 2026 to seek appointment as lead plaintiff, while firms including Levi & Korsinsky, Faruqi & Faruqi, and The Rosen Law Firm are soliciting shareholders and potential whistleblowers.